EW Healthcare Partners
VC Fund
Palo Alto, United States
EW Healthcare Partners is a VC fund in Palo Alto focused on Health Care and Medical. "EW Healthcare Partners has become a partner and advisor to Abiomed and we value the strategic insight and guidance we receive from the team members on various investment and business decisions."
- Total investments:
- 17
- Last investment:
- Lead investor:
- 59%
- Fund size:
- $745M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries EW Healthcare Partners invests in
Stages EW Healthcare Partners invests in
Countries EW Healthcare Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
|
|||
Investment Focus
Industry
- Health Care 10 (59%)
- Medical 7 (41%)
- Biotechnology 7 (41%)
- Medical Device 5 (29%)
- Manufacturing 4 (24%)
Stage
- Funding Round 7 (41%)
- Post-IPO Equity 4 (24%)
- Series B 1 (6%)
- Series C 1 (6%)
- Series D 1 (6%)
Country
- United States 12 (71%)
- Canada 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Robert White
Operating Partner
|
Operating Partner | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Enercon Technologies is an electronics manufacturing company that provides product development, testing, marketing, and design services. | May 18, 2023 | |
|
|
Venus Concept is a progressive thinking company driven by their passion to create cutting edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry.Led by a team of experienced executives and researchers, world renowned for their achievementsin the medical aesthetics industry, Venus Concept is delivering the promise of a more effective, more pleasant and more profitable experience. | $6.7M / Post-IPO Equity / Nov 18, 2022 | |
|
|
VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatientsettings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. | $39M / Series E / Jan 10, 2022 | |
|
|
COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research. | $34M / Series D / Nov 18, 2020 | |
|
|
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. | $72M / Aug 28, 2020 | |
|
|
MiMedx Group is a biopharmaceutical company, develops, and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. MiMedx Group’s proprietary processingmethodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications, OrthoFlo, an amniotic fluid-derived allograft for homologous applications, Physio, a bone grafting material comprising 100% bone tissue with no added carrier, and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. It also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue, AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process, and AmnioFill, a cellular tissue matrix allograft that enhances healing. MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group began operation on February 28, 2008. It has its headquarters in Marietta in Georgia. | $100M / Post-IPO Equity / Jul 02, 2020 | |
|
|
Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successfultrack records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today. | Series B / Jan 22, 2020 | |
|
|
Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $85M / Jan 06, 2020 | |
|
|
Venus Concept is a progressive thinking company driven by their passion to create cutting edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry.Led by a team of experienced executives and researchers, world renowned for their achievementsin the medical aesthetics industry, Venus Concept is delivering the promise of a more effective, more pleasant and more profitable experience. | $28M / Post-IPO Equity / Nov 07, 2019 | |
|
|
Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successfultrack records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today. | Aug 26, 2019 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does EW Healthcare Partners invest in?
EW Healthcare Partners invests primarily in Health Care, Medical and Biotechnology startups, most often at Funding Round and Post-IPO Equity stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact EW Healthcare Partners?
Public channels for EW Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EW Healthcare Partners?
The team at EW Healthcare Partners includes Robert White (Operating Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!